PA1-749

antibody from Invitrogen Antibodies

Targeting: ATXN7 ADCAII, OPCA3, SCA7, SGF73

Provider product page for PA1-749

Western blot

Immunocytochemistry

Immunohistochemistry

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [17]
Comments [0]
Validations
Immunocytochemistry [1]
Flow cytometry [1]
Other assay [18]

Submit

Product number: PA1-749 - Provider product page
Provider: Invitrogen Antibodies
Product name: Ataxin 7 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: PA1-749 detects ataxin 7 protein from transfected cell lysate. PA1-749 has successfully been used in immunohistochemistry and Western blot procedures. By Western blot, this antibody detects an ~96 kDa protein representing human ataxin 7 in transfected COS-1 cells. The PA1-749 immunizing peptide corresponds to amino acid residues 1-17 from human ataxin 7. This sequence is completely conserved in mouse ataxin 7. This peptide (Cat. # PEP-217) is available for use in neutralization and control experiments.
Reactivity: Human, Drosophila
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Concentration: 1 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

ATXN7 protein structure - PA1-749 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. ATXN7 aggregates colocalize with PML bodies in SCA7 transgenic mice. Immunofluorescence analysis of cerebellar Purkinje cells (a) and retinal ganglion neurons (b-d) using antibodies against ATXN7 (affinity-purified polyclonal antibody 1261) and PML (chicken anti-PML antibody). Large ATXN7 aggregates sequestered PML bodies (a and b). In ganglion neurons, PML bodies were also surrounded by (b, yellow arrows), colocalized with (c, arrowheads), or juxtaposed to (d, white arrows) small ATXN7 aggregates. The same ganglion neuron on two different focal plans, shown in panels c and d, displayed distinct colocalization between PML bodies and ATXN7 aggregates. Bars, 5 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5. ATXN7 and Htt-exon1 are efficiently degraded in the presence of PML IV. (A) Western blot and filter assay of FL-74Q alone or coexpressed with PML IV or III in COS-7 cells. (top) Western blot (30 mug protein, anti-ATXN7 1C1, and anti-PML polyclonal). ATXN7 levels strongly decreased in the presence of PML IV (lane 2) but slightly increased with PML III (lane 3). (bottom) Pellet (P) or supernatant (S) fractions of cell extracts (30 mug protein) were filtered, and SDS-insoluble ATXN7 was revealed by anti-ATXN7 1C1. Coexpression of PML IV led to the disappearance of SDS-insoluble aggregates of mutant ATXN7 (lane 2), whereas PML III slightly increased ATXN7 (lane 3 compared with lane 1). (B) RT-PCR. mRNAs were extracted from cells expressing FL-74Q alone (lane 1) or combined with PML IV (lane 2) or III (lane 3). Primers specific to the SCA7 cDNA and the cyclophilin A (Cyclo A) reference cDNA were used for PCR. Coexpression of PML IV or III had no effect on mutant ATXN7 mRNA. (C) Western blot of cells expressing FL-10Q alone (lane 1) or coexpressed with PML IV (lane 2) or III (lane 3). PML IV decreased and PML III slightly increased ATXN7 levels (same antibodies as in A). (D) Western blot of mutant Htt-exon1 expressed in HeLa cells; Htt-exon1 (Ex1) with 125Q alone (lane 1) or with PML IV (lane 2). Levels of Htt-exon1 (detected with antibody 1C2) were strongly decreased when PML IV was coexpressed. (E) Western blot of FMRP expressed in COS-7 cells alone (lane 1) or with PML

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 HDAC3 stabilizes ataxin-7 and enhances post-translational modifications. (A) Ataxin-7-10Q (1-266) and ataxin-7-92Q (1-266) were transiently transfected with HDAC constructs [ 2 - 8 ] in HEK293T cells for 72 hrs. Lysates were collected and separated via SDS-PAGE on 4-12% bis-tris gels. Western blot transfer and analysis with an antibody to ataxin-7 (PA1-749) revealed the presence of bands of expected molecular weight for the ataxin-7 stop constructs as well as bands of higher molecular weight indicated by asterisks, particularly evident in the HDAC3 co-tranfection. GAPDH was used as a loading control. (B) Ataxin-7-10Q, ataxin-7-10Q (1-266), ataxin-7-10Q (1-266) K257R, ataxin-7-92Q, ataxin-7-92Q (1-266) or ataxin-7-92Q (1-266) K257R were co-transfected with vector control or HDAC3 in HEK293T cells. Western blot analysis of cellular lysates with ataxin-7 (PA1-749) antibody revealed the presence of bands corresponding to the wild type, expanded and ataxin-7 1-266 stop mutant. Bands of higher molecular weight were dominant when ataxin-7 was co-transfected with HDAC3 (indicated by asterisks). Note that these bands are diminished in the SUMOylation-deficient ataxin-7 mutant (K257R). beta-actin was used as a loading control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 HDAC3 alters ataxin-7 subcellular localization. (A,B) Expression of ataxin-7 in cytoplasmic and nuclear fractions of HEK293T cells. Cells were transiently transfected with ataxin-7-10Q (wild type), ataxin-7-92Q (expanded) (A) , or the 1-266 N-terminal fragment of wild type and expanded ataxin-7 (B) and cotransfected with vector control (v) or HDAC3. Lysates were subjected to subcellular fractionation followed by western blot analysis of nuclear and cytoplasmic fractions. Ataxin-7 antibody revealed the presence of bands corresponding to the wild type, expanded and stop mutant ataxin-7. Bands of higher molecular weight of ataxin-7 are evident when ataxin-7 is co-expressed with HDAC3 (indicated by asterisks) and present in both nuclear and cytoplasmic fractions. Co-transfection of HDAC3 was confirmed by immunoblotting (data not shown). To ensure equal loading, immunoblotting with GAPDH was used for the cytoplasmic fractions and poly-ADP ribose (PARP) for the nuclear fraction. (C) Immunocytochemistry of transfected HEK293T cells. Cells were fixed and stained with antibodies to ataxin-7 conjugated to Alexa 488 (green), HDAC3 conjugated to Alexa 555 (red), and counterstained with DAPI (blue). Only the ataxin-7 and DAPI expression are shown, although co-transfection of HDAC3 was determined by visualization of the red track when appropriate. Cells were imaged using confocal microscopy to elucidate colocalization of ataxin-7 and DAPI. Scale bar represents 5 mum. (D) Quantific

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Role of HDAC3 deacetylase activity in ataxin-7 post-translational modification and subcellular localization. (A) Ataxin-7-10Q, ataxin-7-10Q (1-266), ataxin-7-92Q or ataxin-7-92Q (1-266) were cotransfected with vector control or HDAC3 or a catalytically-inactive mutant of HDAC3, HDAC3 (H134A/H135A), in HEK293T cells. Western blot analysis of cellular lysates with ataxin-7 (PA1-749) antibody revealed the presence of bands corresponding to the wild type, expanded and stop mutant ataxin-7. Bands of higher molecular weight that are detected when ataxin-7 is co-expressed with HDAC3 (indicated by asterisks) are also present when ataxin-7 is co-expressed with the catalytically-inactive HDAC3 mutant. Co-expression of HDAC3 was confirmed by immunoblotting (HDAC3 antibody sc17795; data not shown) and GAPDH was used as a loading control. (B) Immunocytochemistry of HEK293T cells transiently transfected with ataxin-7-10Q (wild type) or ataxin-7-92Q (expanded), and co-transfected with HDAC3 or the catalytically-inactive mutant HDAC3 (H134A/H135A). Cells were fixed and stained with antibodies to ataxin-7 conjugated to Alexa 488 (green), HDAC3 conjugated to Alexa 555 (red), and counterstained with DAPI (blue). Cells were imaged using confocal microscopy to elucidate colocalization of ataxin-7 and HDAC3, which can be detected by yellow co-staining. Scale bar represents 5 mum wild type.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Reduction of ataxin-7 mRNA in the SCA7 mouse retina. (a) Relative levels of human (top panel) or mouse (bottom panel) ataxin-7 mRNA levels one month post-injection with AAV2/1 miC or miS4. (b) Representative western blot demonstrating mutant human (upper band, denoted by arrow) and mouse ataxin-7 (lower band) protein levels one month post injection of AAV2/1 miC or miS4. For quantification (c), ataxin-7 protein levels were normalized to beta-actin (upper panel, human protein; lower panel, mouse protein). For all panels, results are represented as mean +-SEM (n = 3), ***p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 ATXN7 expression in human fibroblasts. ( A ) Western blot analysis of ataxin-7 levels in control (F1, F2 and F3) and spinocerebellar ataxia type 7 (SCA7) fibroblasts. Representative blot is shown and a graph presenting quantitation based on analyses from three separate protein isolations. In the case where the expression level of individual alleles was analyzed separately, clear bars represent normal allele and hatched bars represent mutant allele; ( B ) Quantitative Reverse transcription polymerase chain reaction (qRT-PCR) analysis of total ATXN7 mRNA levels in control and SCA7 fibroblasts; ( C ) Representative images of anti-ataxin-7 immunofluorescence (IF) in fibroblast cell lines (control: GM07492 and SCA7). Scale bar = 25 mum. 4',6-diamidino-2-phenylindol (DAPI) staining of the nuclei is in blue.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 HDAC3 and ataxin-7 physically interact and colocalize. (A) Immunoprecipitation of HEK293T cells transiently transfected with ataxin-7-10Q (wild type) or ataxin-7-92Q (expanded), or vector. Whole cell lysates were subject to immunoprecipitation with an antibody to ataxin-7 (PA1-749), separated by SDS-PAGE and immunoblotted with an antibody to HDAC3 (N-19). (B) Reverse immunoprecipation with HDAC3 (B-12) and western blotting with ataxin-7 (K) supports the binding of ataxin-7 to HDAC3. (C) Immunocytochemistry of HEK293T cells transiently transfected with ataxin-7-10Q (wild type) or ataxin-7-92Q (expanded), and co-transfected with HDAC3. Cells were fixed and stained with antibodies to ataxin-7 conjugated to Alexa 488 (green), HDAC3 conjugated to Alexa 555 (red), and counterstained with DAPI (blue). Cells were imaged using confocal microscopy to elucidate colocalization of ataxin-7 and HDAC3. Scale bar represents 10 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4. SCA7 Stem Cell Neural Derivatives Exhibit PolyQ Length-Dependent Disease Phenotypes (A) Graph of average mitochondrial length of control (10Q) and SCA7 patient (50Q, 65Q, 70Q) neuronal progenitor cells (NPCs) on the basis of Tom20 immunostaining. Quantification of average mitochondrial length analyzed using ImageJ mitochondrial morphometry plugin. Each dot represents the average mitochondrial length from an individual cell, and data are represented as mean +- SEM. Two control patient lines (one or two clones per line) and two SCA7 patient lines (two clones per line); n = 70-100 cells/genotype. ***p < 0.001 (one-way ANOVA with post hoc Tukey's multiple-comparison test). (B) Ataxin-7-knockout NPCs were transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector. Non-transduced (NT) cells serve as a negative control for transfection. Protein lysates were immunoblotted with anti-ataxin-7 or antiexpanded polyQ tract antibody, as indicated. beta-Actin immunoblotting analysis was performed as a loading control. (C) Protein lysates from control and SCA7 patient NPCs of the indicated CAG repeat allele size were filtered through nitrocellulose and then immuno-blotted with anti-expanded polyQ tract antibody. (D) Protein lysates from non-transduced ataxin-7-knockout NPCs or from ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector were filtered through nitrocellulose and then immunoblotted with anti-expanded po